Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. (RFL)
| Cash Flow | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Depreciation and amortization | 48 | 55 | 50 | 288 |
| (gain) loss on sale of property and equipment | 0 | 0 | 54 | -81 |
| Change in deferred income taxes | NaN | NaN | NaN | -165 |
| Gain on settlement of accounts payable and convertible notes payable | 3,723 | 201 | 34 | NaN |
| Stock-based compensation | 172 | 387 | 598 | 2,123 |
| Gain on dtlm sale transactions | NaN | NaN | NaN | 30 |
| Trade accounts receivable | -1 | -118 | -214 | 151 |
| Inventory | 5 | -1 | -9 | 11 |
| Prepaid expenses and other current assets | -1 | 360 | -273 | -818 |
| Prepaid clinical trial costs (current and non-current) | -310 | 1,260 | -231 | -112 |
| Other receivables | 0 | 0 | -1,206 | 273 |
| Other assets | 52 | -1 | -5 | -28 |
| Accounts payable and accrued expenses | -1,138 | 505 | 457 | -922 |
| Other current liabilities | 4 | 3 | -3 | -67 |
| Due to related parties | -18 | -18 | 28 | -10 |
| Accrued expenses, noncurrent | 0 | -415 | 3 | 913 |
| Convertible notes payable | 14 | -12 | 8 | 5 |
| Consolidated net loss | -2,898 | -6,327 | -9,797 | -30,643 |
| Amortization of discount on available-for-sale securities | 0 | 0 | 0 | -285 |
| Loss on impairment of goodwill | 0 | 0 | NaN | 3,050 |
| Unrealized loss on equity investments - cyclo | 0 | 0 | 0 | -5,144 |
| Gain on dtlm sale transactions | 0 | NaN | NaN | NaN |
| Interest receivable | 0 | 0 | 0 | -515 |
| Other liabilities | 0 | 0 | 0 | 15 |
| Realized gain on available-for-sale securities | 0 | 0 | 0 | 178 |
| Unrealized loss on convertible notes, due from cyclo | 0 | 0 | 0 | -719 |
| Net unrealized gain on investments - hedge funds | NaN | NaN | NaN | 0 |
| Realized loss on investment in equity securities | NaN | NaN | NaN | 0 |
| Loss on initial investment in day three upon acquisition | NaN | NaN | NaN | 0 |
| Realized gain on equity investments - cyclo | NaN | NaN | NaN | 0 |
| Recovery of receivables from cornerstone | NaN | NaN | NaN | 0 |
| In-process research and development expense | NaN | NaN | NaN | 0 |
| Gain on dissolution of a business | NaN | NaN | NaN | 0 |
| Equity in loss of day three | NaN | NaN | NaN | 0 |
| Credit loss expense | NaN | NaN | NaN | 0 |
| Net cash used in operating activities | -7,284 | -7,523 | -6,806 | -18,924 |
| Purchase of property and equipment | 0 | 5 | 0 | 4 |
| Proceeds from sale of property and equipment | 6 | 0 | 70 | 13 |
| Purchase of preferred shares and warrants from nina medical | 0 | 250 | 500 | NaN |
| Purchases of available-for-sale securities | 0 | 0 | 0 | 16,988 |
| Proceeds from the sale and maturities of available-for-sale securities | 0 | 0 | 0 | 80,694 |
| Purchase of intangible assets | 0 | 0 | 0 | 17 |
| Payments for convertible notes receivable, due from cyclo | NaN | NaN | NaN | 19,500 |
| Issuance of convertible notes, due from cyclo | 0 | 0 | 0 | NaN |
| Cash paid in cyclo merger, net of cash acquired | 0 | NaN | NaN | 2,709 |
| Proceeds from hedge funds | 0 | 0 | NaN | 2,547 |
| Proceeds from day three patent sale | NaN | NaN | NaN | 0 |
| Proceeds from sales of equity securities | NaN | NaN | NaN | 0 |
| Issuance of convertible notes receivable, due from cyclo | NaN | NaN | NaN | 0 |
| Purchase of investments in cyclo | NaN | NaN | NaN | 0 |
| Issuance of convertible note receivable | NaN | NaN | NaN | 0 |
| Issuance of day three promissory notes | NaN | NaN | NaN | 0 |
| Proceeds from investments - other pharmaceuticals | NaN | NaN | NaN | 0 |
| Cash acquired in acquisition of day three, net of cash payments | NaN | NaN | NaN | 0 |
| Cash acquired in the cornerstone acquisition, net of cash payments | NaN | NaN | NaN | 0 |
| Net cash (used in) provided by investing activities | 6 | -255 | -430 | 44,035 |
| Payments for taxes related to shares withheld for employee taxes | 19 | 32 | 28 | 215 |
| Proceeds from issuance of common stock in rights offering, net of transaction costs | NaN | NaN | NaN | 25,001 |
| Proceeds from sale of rafael medical devices membership units | NaN | NaN | NaN | 44 |
| Principal payments on installment note payable | NaN | NaN | NaN | 0 |
| Cash paid to settle convertible notes payable | 9 | 0 | 2 | NaN |
| Purchases of treasury stock | NaN | NaN | NaN | 0 |
| Proceeds from sale of rafael medical devices membership units | 0 | NaN | NaN | NaN |
| Net cash used in financing activities | -28 | -32 | -30 | 24,830 |
| Effect of exchange rate changes on cash and cash equivalents | 24 | 50 | 36 | 153 |
| Net (decrease) increase in cash and cash equivalents | -7,282 | -7,760 | -7,230 | 50,094 |
| Cash and cash equivalents, beginning of period | 37,779 | 45,539 | 52,769 | 2,675 |
| Cash and cash equivalents, end of period | 30,497 | 37,779 | 45,539 | 52,769 |